Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, et al.
The Lancet (2021) Vol. 399, Iss. 10319, pp. 61-116
Open Access | Times Cited: 169

Showing 1-25 of 169 citing articles:

Global epidemiology of cirrhosis — aetiology, trends and predictions
Daniel Q. Huang, Norah A. Terrault, Frank Tacke, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 388-398
Open Access | Times Cited: 357
Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S32-S42
Open Access | Times Cited: 297
Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses
Melissa M. Lane, Elizabeth Gamage, Shutong Du, et al.
BMJ (2024), pp. e077310-e077310
Open Access | Times Cited: 210
Noninvasive proteomic biomarkers for alcohol-related liver disease
Lili Niu, Maja Thiele, Philipp E. Geyer, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1277-1287
Open Access | Times Cited: 174
Lifestyle interventions in nonalcoholic fatty liver disease
Zobair M. Younossi, Shira Zelber‐Sagi, Linda Henry, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 11, pp. 708-722
Closed Access | Times Cited: 124
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 82
Understanding the cellular interactome of non-alcoholic fatty liver disease
Sebastian Wallace, Frank Tacke, Robert F. Schwabe, et al.
JHEP Reports (2022) Vol. 4, Iss. 8, pp. 100524-100524
Open Access | Times Cited: 77
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
Alina M. Allen, Jeffrey V. Lazarus, Zobair M. Younossi
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 209-217
Open Access | Times Cited: 75
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 45
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Diabetologia (2024)
Open Access | Times Cited: 16
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
Einar S. Björnsson, Camilla Stephens, Edmond Atallah, et al.
Liver International (2022) Vol. 43, Iss. 1, pp. 115-126
Open Access | Times Cited: 46
Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 844-850
Open Access | Times Cited: 30
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Piero Portincasa
Internal and Emergency Medicine (2023) Vol. 18, Iss. 4, pp. 993-1006
Open Access | Times Cited: 25
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Dimitrios D. Raptis, Christos S. Mantzoros, Stergios A. Pοlyzos
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 77-96
Open Access | Times Cited: 22
Influence of sex in alcohol‐related liver disease: Pre‐clinical and clinical settings
Debora Bizzaro, Chiara Becchetti, Silvia Trapani, et al.
United European Gastroenterology Journal (2023) Vol. 11, Iss. 2, pp. 218-227
Open Access | Times Cited: 22
The Impact of Stigma on Quality of Life and Liver Disease Burden Among Patients with Nonalcoholic Fatty Liver Disease
Zobair M. Younossi, Saleh A. Alqahtani, Jesús Funuyet‐Salas, et al.
JHEP Reports (2024) Vol. 6, Iss. 7, pp. 101066-101066
Open Access | Times Cited: 13
Envisioning how to advance the MASH field
Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, et al.
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 12
Global burden of liver cirrhosis 1990–2019 and 20 years forecast: results from the global burden of disease study 2019
Yikai Wang, Muqi Wang, Chenrui Liu, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 10
Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis
Sue Shea, Christos Lionis, Chris Kite, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 9
Screening for liver fibrosis: lessons from colorectal and lung cancer screening
Maja Thiele, Patrick S. Kamath, Isabel Graupera, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 7, pp. 517-527
Closed Access | Times Cited: 8
A Healthful Plant-Based Diet as an Alternative Dietary Approach in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Gabriele Castelnuovo, Nuria Pérez-Díaz-del-Campo, Chiara Rosso, et al.
Nutrients (2024) Vol. 16, Iss. 13, pp. 2027-2027
Open Access | Times Cited: 7
Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study
Kiminori Kimura, Tatsuya Kanto, Shinji Shimoda, et al.
EBioMedicine (2022) Vol. 80, pp. 104069-104069
Open Access | Times Cited: 32
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association
Manon Allaire, Jordi Bruix, Marko Korenjak, et al.
JHEP Reports (2022) Vol. 4, Iss. 12, pp. 100578-100578
Open Access | Times Cited: 32
Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life
Marta Carol, Martina Pérez, Elsa Solà, et al.
PLoS ONE (2022) Vol. 17, Iss. 4, pp. e0265153-e0265153
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top